Efficacy of frequent high dose dexamethasone in treatment of primary immune thrombocytopenic purpura
Phase 2
- Conditions
- ewly diagnosed immune thrombocytopenic purpura.Immune thrombocytopenic purpura
- Registration Number
- IRCT2015110424881N1
- Lead Sponsor
- Vice chancellor for research, Zahedan University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
All Primary and newly diagnosed immune thrombocytopenic purpura patients enrolled the study.
Platelet count less than 20000; platelet count more than 20000 in cases with bleeding.
Exclusion criteria: comorbidities such as diabetes; liver or renal disease; HIV; Previous history of immune thrombocytopenic purpura; recently use of steroids; history of systemic lupus erythmatous;
No consent (declining) for participating in study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet count. Timepoint: Monthly till 12 months after treatment course. Method of measurement: Cell Blood Count; Platelet count.
- Secondary Outcome Measures
Name Time Method Blood pressure. Timepoint: Monthly after treatment and every 15 min during dexamethasone courses. Method of measurement: By manometer.